1.Alternative Name：ERBB2,CD340
2.Target：HER2
3.Source：Human HER2 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence：Thr23-Thr652
5.Protein structure:P04626hFC
6.Molecular Characterization:The protein has a calculated MW of 95kDa.The reducing (R) heterodimer protein migrates as 100-130 kDa due to glycosylation
7.Purity:SDS-PAGE>95%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.

11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 95%.
13.ELISA

When Recombinant Human HER2/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Pertuzumab (Cat.No. B162801.abinvivo) that produces 50% of the optimal binding response is approximately 9 ng/ml.
14.SPR

Anti-Human HER2 (Pertuzumab)（Cat.No.B162801）captured on CM5 chip , can bind Recombinant Human HER2/hFC Protein（Cat.No.B152702）with a KD constant of 8.15E-11 M, determined in a SPR assay .
15.Note：For research use only .